ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chengdu Kanghong Pharmaceutical Group Co., Ltd. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 33 studies whose lead sponsor is Chengdu Kanghong Pharmaceutical Group Co., Ltd. or one of 2 companies grouped under it. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 3, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Chengdu Kanghong Pharmaceutical Group with Takeda and CSPC Pharmaceutical Group →

Pipeline: 5 programs

Each counted once: 5 with a study Chengdu Kanghong Pharmaceutical Group Co., Ltd. leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Chengdu Kanghong Pharmaceutical Group Co., Ltd.’s own registered studies; Chengdu Kanghong Pharmaceutical Group Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Chengdu Kanghong Pharmaceutical Group Co., Ltd.’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

1 of Chengdu Kanghong Pharmaceutical Group Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 1J
  9. J
  10. A
  11. S
  12. O
  13. N

Add it to your calendar (.ics) → With an account.

All 33 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1030%Not yet recruiting 9 · Recruiting 1
  • Completed824%
  • Stopped early26%
  • Status unknown or other1339%

Phase

  • Phase 310
  • Phase 110
  • Phase 210
  • Phase 42

Where

  • China22
  • Israel2
  • United States2
  • Philippines1
  • Austria1
  • Hungary1

Over the years

  1. 09
  2. 10
  3. 11
  4. 12
  5. 13
  6. 14
  7. 15
  8. 16
  9. 17
  10. 18
  11. 19
  12. 20
  13. 21
  14. 22
  15. 23
  16. 24
  17. 525
  18. 526

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chengdu Kanghong Pharmaceutical Group Co., Ltd.

  • Chengdu Kanghong Biotech Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    21 studies →
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies
  • IOPtima Ltd.
    Acquired — became part of Chengdu Kanghong Pharmaceutical Group Co., Ltd., Oct 1, 2018 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Studies

Recruiting first, then most recently updated. Showing 33 of 33.